Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:STSA

Satsuma Pharmaceuticals (STSA) Stock Price, News & Analysis

Satsuma Pharmaceuticals logo

About Satsuma Pharmaceuticals Stock (NASDAQ:STSA)

Advanced Chart

Key Stats

Today's Range
$1.10
$1.10
50-Day Range
$1.04
$1.11
52-Week Range
$0.59
$8.08
Volume
N/A
Average Volume
701,788 shs
Market Capitalization
$36.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Receive STSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

STSA Stock News Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Satsuma Pharmaceuticals Inc (STSA)
SNBL’s Subsidiary Resubmits Migraine Drug Application
See More Headlines

STSA Stock Analysis - Frequently Asked Questions

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) issued its quarterly earnings data on Tuesday, November, 9th. The financial services provider reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09.

Satsuma Pharmaceuticals (STSA) raised $75 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Satsuma Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

Last Earnings
11/09/2021
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Regional Banks
Current Symbol
NASDAQ:STSA
Fax
N/A
Employees
21
Year Founded
2016

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$70.06 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.41 per share
Price / Book
0.78

Miscellaneous

Free Float
22,809,000
Market Cap
$36.47 million
Optionable
Not Optionable
Beta
0.10

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:STSA) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners